Bessor Pharma

Bessor Pharma Receives SBIR Grant for New Pancreatitis Treatment

BESSOR PHARMA RECEIVES $300,000 PHASE 1 SBIR GRANT TO DEVELOP NOVEL TREATMENT FOR PANCREATITIS Framingham, MA, November 22, 2016 - Bessor Pharma has received a $300,000 Phase 1 Small Business Innovation Research Grant (SBIR) from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), to develop a new therapeutic for acute pancreatitis, the ...READ MORE
Continue Reading By

Bessor Receives STTR Grant for Therapeutic to Treat Chemotherapy-Induced Kidney Damage

BESSOR PHARMA RECEIVES $219,000 PHASE 1 STTR GRANT TO DEVELOP NOVEL TREATMENT TO PREVENT CHEMOTHERAPY-INDUCED TISSUE DAMAGE Framingham, MA, September 23, 2014 - Bessor Pharma has received a $219,000 Phase 1 Small Business Technology Transfer grant (STTR) from the National Cancer Institute (NCI), to develop a new therapeutic to prevent and treat kidney damage induced ...READ MORE
Continue Reading By